Rosacea

Earlier this week, we shared our first Rosacea Awareness Month quiz. Review the answers and your responses below.

This Rosacea Awareness Month, take a look at previous coverage from 2024.

This Rosacea Awareness Month, we have compiled a list of resources for clinicians to share with their rosacea patients.

Click here to read more and answer our quiz questions in recognition of Rosacea Awareness Month.

One study uncovered high levels of CGRP in patients with rosacea, with levels not affected by age, sex, BMI, and other factors.

The anticipated PDUFA date is November 4, 2024.

Alongside expert dermatologists, the NRS recently developed a Seal of Acceptance for skin care and cosmetic products clinically tested and evaluated for patients with rosacea.

The study explored the potential role of hormonal changes, specifically estrogen levels, in the pathogenesis of rosacea.

The filing is supported by positive phase 3 clinical trial data.

Researchers observed lower levels of serum gamma linolenic acid in patients with rosacea.

Grants allow investigators to uncover the potential causes and key aspects of rosacea to pave the way for improved treatment, prevention, and possibly a cure.

Additionally, investigators found that several patients in the review had rosacea induced or exacerbated by the use of topical corticosteroids on the face.

She shares her top 5 considerations for all dermatology drug prescribers.

The condition may present as a manifestation of pediatric rosacea.

While botulinum toxin has emerged as a treatment course for rosacea in recent years, researchers are calling for more comprehensive and detailed long-term research to assess its effectiveness.

Skin responses to lactic acid sting and capsaicin tests varied, according to researchers.

The National Rosacea Society survey revealed only 3% of patients had coverage for laser treatments.

Based on the positive topline phase 3 results, Journey Medical plans to submit a New Drug Application to the FDA in the second half of 2023.

Safety data is promising, but clinicians are encouraged to utilize proper skin cooling mechanisms.

John Barbieri, MD, MBA, FAAD, discusses his SDPA Annual Summer Dermatology Conference sessions, "Foundational Tools for Acne and Rosacea Management," and "Neutraceuticals and Cosmeceuticals: Which to Choose?"

Del Rosso previews his upcoming sessions at SCALE 2023 discussing the latest updates in management and treatment techniques.

Researchers investigated the effects of combination mesoderm therapy and compound glycyrrhizin injections in patients with rosacea.

When compared to a vehicle treatment, patients with rosacea being treated with oxymetazoline had a more significant reduction facial erythema.

The American Acne and Rosacea Society is spotlighting the issue as part of Rosacea Awareness Month.

April is National Rosacea Month. Recent data has indicated a correlation between rosacea and certain cardiovascular, neurologic, endocrine, and gastrointestinal disorders. Steve Daveluy, MD, FAAD shares insight on that, plus several new and exciting therapies available.

April has been designated Rosacea Awareness Month by The National Rosacea Society (NRS) in an effort to educate the public on the impact of this chronic and widespread facial disorder.

The Dermatology Times® team is spotlighting rosacea treatments during this Rosacea Awareness Month.

A recent study published in Clinical and Experimental Dermatology observed a link between menopause and rosacea and found that menopausal flushing can exacerbate and precipitate rosacea.

At the 2022 Fall Clinical Dermatology Conference, Valerie D. Callender, MD, FAAD, presents “What’s Hot in Acne & Rosacea.”

Topline data expected in the first half of 2023.